Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised, Double-blind, Parallel-group, Flexible-dose Trial Evaluating the Efficacy and Safety of 12 Weeks of Treatment With Sertindole or Olanzapine in Patients With Schizophrenia in Asia
Brief Summary: The purpose of this study is to assess the efficacy and safety of sertindole in patients with schizophrenia in Asia.


Options:
A: Inclusion Criteria:

1. DSM-IV criteria for chronic schizophrenia or schizoaffective disorder
2. Sub-optimal treatment-response
3. Total score \> 60 on the Positive and Negative Syndrome Scale (PANSS) at baseline of run-in phase and again at baseline of double blind phase
4. Age 18-64 years old
5. Signed informed consent
6. Patient is in good general medical health

Exclusion criteria:

1. History of failure to respond to 400 mg/day or more of clozapine for 8 contiguous weeks
2. History of failure to respond to quetiapine treatment at dosages \> 1200 mg daily for 6 contiguous weeks
3. History of quetiapine intolerance (e.g., clinically significant leukopenia or agranulocytosis, or severe dystonic reactions)
4. Significant recent history of violence or suicidal activity, which required \> 4 episodes of PRN anti-agitation medication per week
5. Mental retardation
6. Depot antipsychotic within 30 days before randomization
7. Significant medical illness requiring frequent dose adjustment or medication changes

Clozapine non-responders are explicitly excluded, as they would be unlikely to show a response in this study.
B: Inclusion Criteria:

* Inclusion Criteria: Men and women, age 18-65 years with persistent positive or negative symptoms with a PANSS total score of ≥ 70 and \< 110 and a Clinical Global Improvement (CGI)- Severity of Illness score of at least 4 (moderately ill) at screening. Subjects may be treated as in- or out-patients. Subjects must give written informed consent.

Exclusion Criteria:

* Subjects with other psychiatric, medical or behavioural comorbid disorder that may interfere with study conduct or interpretation.
* Female of childbearing potential, unless the subject is using a reliable method of contraception
* Subjects with alcohol or psychoactive-substance dependence not in full remission or with significant alcohol or substance abuse in the past 3 months will be excluded.
* Laboratory test results outside the range of reference considered by the investigator to be clinically significant.
* Inability to respect the visit schedule and known intolerance to quetiapine at 800mg/day.
C: Inclusion Criteria:

* Male and female patients, aged 18-65 years (extremes included), suffering from schizophrenia
* Positive and Negative Syndrome Scales (PANSS) total score between 60 and 120 (extremes included) at screening and baseline
* Based on the patient's clinical status, an antipsychotic treatment is indicated
* Otherwise healthy
* Female patients of non-childbearing potential, or non-pregnant, not breast-feeding women of childbearing potential, using adequate birth control methods

Exclusion Criteria:

* Current Axis I primary psychiatric diagnosis other than schizophrenia
* Has never before received antipsychotic drugs
* Has received a depot antipsychotic medication within less than one dose interval prior to Screening
* History of clinically significant cardiovascular disease, congestive heart failure, cardiac hypertrophy, arrhythmia or bradycardia (\<50 beats per minute)
* Congenital long QT syndrome or a family history of this disease, or in patients with known acquired QT interval prolongation (QTc above 450 msec in males and 470 msec in females at Screening)
* Significant risk of suicide and/or violent behaviour
* Known history of narrow angle glaucoma
* Substance or alcohol abuse, current alcohol dependence
* Use of disallowed concomitant medication

Other protocol-defined inclusion and exclusion criteria may apply.
D: Inclusion Criteria:

* Patients must demonstrate acute psychopathologic severity criteria and be at least moderately ill.
* Patients must have experienced an exacerbation of their illness within the previous 2 weeks.
* Patients in whom a switch to another antipsychotic medication is acutely indicated.

Exclusion Criteria:

* Patients who are deemed nonresponsive to risperidone or olanzapine.
* Patients who have been hospitalized for greater than 2 weeks immediately prior to Visit 1.
* Patients having received olanzapine or risperidone in the past 30 days.
* Treatment with clozapine within 1 year prior to Visit 1.
* Diagnosis of substance-induced psychosis by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria within 7 days of Visit 1 (or at any time during the study), or confirmed on clinical grounds within 72 hours subsequent to Visit 1 (or at any time during the study).
* A diagnosis of Parkinson's disease, dementia-related psychosis, or related disorders.

Answer: C